Enables a more targeted delivery at the tumor site of cisplatin
LiPlaCis® is a unified product consisting of the LiPlaCis drug and its DRP®, Oncology Venture’s unique companion diagnostic.
The LiPlaCis drug is an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin, which has documented efficacy in numerous tumor types.
The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed.
2X-121 has a novel dual-inhibitory action against both PARP 1/2 and Tankyrase 1/2
2X-121 is a unified product consisting of a PARP inhibitor and its DRP®, Oncology Venture’s unique companion diagnostic.
The drug is an investigational, orally-available small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells.
Dovitinib is an investigational orally active small molecule multi-kinase inhibitor that exhibits potent activity against multiple RTKs involved in tumor growth and angiogenesis.
Dovitinib is a unified product consisting of a active small molecule multi-kinase inhibitor and its DRP®, Oncology Venture’s unique companion diagnostic.
The dovitinib drug binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells.
Glutathione-enhanced, PEGylated Liposomal Doxorubicin
2X-111 is a unified product consisting of liposomal doxorubicin and its accompanying DRP®, Oncology Venture’s unique companion diagnostic.
This novel drug candidate is designed for the liposomal delivery of the anti-cancer drug doxorubicin directly to a tumor, with a glutathione coating added to exploit active endogenous transporters, allowing the drug to cross the blood-brain barrier.
This drug candidate is a synthetic drug candidate based on a naturally occurring substance that exploits a deficiency in the DNA repair mechanism of cancer cells in a manner similar to a PARP inhibitor.
Irofulven is a unified product consisting of a synthetic drug and an accompanying DRP®, Oncology Venture’s unique companion diagnostic.
The irofulven drug alkylates DNA and protein macromolecules, forms adducts, and arrests cells in the S-phase of the cell cycle. This agent requires NADPH-dependent metabolism by alkenal/one oxidoreductase for activity.
APO010 is a novel, investigational systemic chemotherapeutic treatment targeting multiple myeloma, a systemic malignancy in the blood that affects plasma cells.
APO010 is a unified product consisting of a systemic chemotherapeutic treatment and its DRP®, Oncology Venture’s unique companion diagnostic.
The human immune system can kill cancer cells using a certain type of white blood cells called cytotoxic T lymphocytes (CTLs). One way CTLs kill cancer cells is programmed cell death (apoptosis). A Fas ligand (FasL) on the CTL binds to a death receptor (CD95) on the target cell. This triggers apoptosis.
Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and thereby acts on the microtubule structure and function of the cell. Oncology Venture's Ixempra study has not yet commenced.
Ixempra (US), owned by R-Pharm
Ixempra® seeks to block the ability of cells to modify the internal ‘skeleton’ that they need to divide and multiply. When the skeleton is unable to change, the cancer cells cannot divide and eventually die. Both cancer cells and non-cancer cells, such as nerve cells, is affected by Ixempra®, which could cause side effects.